Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.65 |
| ▸ | THRB | P10828 | 8/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.65 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.54 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822126 | 0.88 | TGFBR1 (0.66) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL3948027 | 0.86 | TGFBR1 (0.70) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL3949757 | 0.84 | TGFBR1 (0.59) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL4819301 | 0.81 | TGFBR1 (0.79) | TGFBR1THRBMAPK14 | |
| SCHEMBL24682169 | 0.80 | TGFBR1 (0.89) | TGFBR1THRBMAPK14 | |
| SCHEMBL13899378 | 0.80 | THRB (0.55) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL373535 | 0.79 | TGFBR1 (1.00) | TGFBR1THRBMAPK14 | |
| SCHEMBL29832286 | 0.79 | TGFBR1 (1.00) | TGFBR1THRBMAPK14 | |
| SCHEMBL4822158 | 0.77 | TGFBR1 (0.64) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL4822080 | 0.77 | TGFBR1 (0.66) | TGFBR1THRBMAPK14TGFBR2MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| US-20170119682-A1 | MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170119682-A1 | MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20150289795-A1 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ES) | 2015-10-15 | — | — | US | disclosed |
| US-20150289795-A1 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ES) | 2015-10-15 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812450-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150289795-A1 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER | IL6ST, TGFBR2, TSG101 | TGFBR1 8/4885THRB 399/4885MAPK14 3086/4885 |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | EXOSC9, EXOSC5, EXOSC10 | TGFBR1 2539/4885THRB 4617/4885MAPK14 3026/4885 |
| US-20080262004-A1 | Tgf-Beta Inhibitors | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885THRB 108/4885MAPK14 2372/4885 |
| US-20170119682-A1 | MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES | EXOSC9, EXOSC5, EXOSC10 | TGFBR1 2539/4885THRB 4617/4885MAPK14 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.